Investment Thesis
Neumora is a pre-revenue biotech company with a strong balance sheet ($147.1M cash) and approximately 3.2 years of cash runway at current burn rates. However, the absence of revenue, significant operating losses (-$52.9M), and negative cash flow (-$46.4M annually) mean the investment thesis depends entirely on unvalidated pipeline success with no fundamental profitability metrics to assess.
Strengths
- Strong cash position of $147.1M provides substantial operating runway
- Excellent liquidity ratios (5.09x current ratio) with minimal near-term solvency risk
- Moderate leverage (0.75x debt/equity) with reasonable financial flexibility
- Minimal capital expenditure ($16.0K) suggests focused R&D without manufacturing burden
Risks
- Pre-revenue stage with no revenue generation or path to profitability visible
- High annual operating burn of $46.4M will deplete cash reserves within 3-4 years if not addressed
- Negative ROE (-75.6%) and ROA (-34.7%) reflect value destruction without offsetting revenue
- Complete dependence on clinical trial success and future product commercialization for survival
- Interest coverage ratio of -36.8x indicates debt service sustainability concerns
Key Metrics to Watch
- Cash burn rate trend and runway depletion timeline
- Operating loss trajectory and path to revenue generation
- Clinical trial progress and regulatory milestones for pipeline programs
- Debt refinancing or additional capital raise requirements and terms
Financial Metrics
Revenue
N/A
Net Income
-53.5M
EPS (Diluted)
$-0.30
Free Cash Flow
-46.4M
Total Assets
153.9M
Cash
147.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-75.6%
ROA
-34.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
5.09x
Quick Ratio
5.09x
Debt/Equity
0.75x
Debt/Assets
54.1%
Interest Coverage
-36.81x
Long-term Debt
53.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:57:08.454456 |
Data as of: 2026-03-31 |
Powered by Claude AI